Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lovenox Clears FDA For STEMI After Priority Review

This article was originally published in The Pink Sheet Daily

Executive Summary

The low molecular weight heparin joins Plavix in the STEMI space.

You may also be interested in...

Momenta Pharmaceuticals CEO Craig Wheeler: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

Exec outlines the company's efforts to get generic of Sanofi-Aventis' Lovenox to market, its partnership with Sandoz involving biogenerics and other business strategy initiatives.

Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely

Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.

Sanofi-Aventis' Lovenox sNDA Granted Priority Review

Sanofi's low molecular weight heparin has an early June user fee date for a STEMI claim.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts